Department of Gynaecology and Obstetrics, Aarhus University Hospital, Denmark.
Department of Infectious Diseases, Aarhus University Hospital, Denmark.
Gynecol Oncol. 2014 Jun;133(3):454-9. doi: 10.1016/j.ygyno.2014.04.004. Epub 2014 Apr 12.
The aims of this study are to investigate the actual time from primary surgery for epithelial ovarian cancer (OC) to initiation of chemotherapy (TI) amongst Danish women in 2005-2006, and to compare the survival for groups with early initiation (≤median TI) and late initiation of adjuvant chemotherapy (>median TI).
All Danish women who underwent surgery for OC in the period 1 January 2005 to 31 December 2006 and recorded in the Danish Gynaecological Cancer Database (DGCD) were included. The five-year survival was estimated overall and by TI exposure. The Cox proportional hazard regression analysis was used to compute the adjusted hazard ratio (HR).
The median TI was 32days (25-75% quartile: 24days; 41days). The strongest prognostic factors for death were residual tumour and the International Federation of Obstetrics and Gynecology (FIGO) stage. The unadjusted HR for death in patients with TI>32days compared with TI≤32days was 0.85 (95% CI: 0.70; 1.04), p-value 0.12. When adjusted for residual tumour and FIGO-stage the HR was 1.13 (95% CI: 0.92; 1.39), p-value 0.26. The overall five-year survival was 42.8%, (95% CI: 38.9%; 46.5%).
This nationwide population-based cohort study revealed a non-significant increased risk of death for patients with TI>32days compared with the reference TI≤32days. The strongest prognostic factors were residual tumour after surgery and FIGO-stage. The overall five-year survival was 42.8% (95% CI: 38.9%; 46.5%).
本研究旨在调查丹麦女性在 2005 年至 2006 年期间上皮性卵巢癌(OC)初次手术后至开始化疗(TI)的实际时间,并比较早期(≤中位数 TI)和晚期(>中位数 TI)开始辅助化疗的生存情况。
所有在 2005 年 1 月 1 日至 2006 年 12 月 31 日期间接受 OC 手术且记录在丹麦妇科癌症数据库(DGCD)中的丹麦女性均被纳入本研究。总体及按 TI 暴露情况估计 5 年生存率。采用 Cox 比例风险回归分析计算调整后的危险比(HR)。
中位 TI 为 32 天(25-75%四分位数:24 天;41 天)。死亡的最强预后因素是残余肿瘤和国际妇产科联盟(FIGO)分期。与 TI≤32 天相比,TI>32 天患者死亡的未调整 HR 为 0.85(95%CI:0.70;1.04),p 值为 0.12。当调整残余肿瘤和 FIGO 分期后,HR 为 1.13(95%CI:0.92;1.39),p 值为 0.26。总体 5 年生存率为 42.8%(95%CI:38.9%;46.5%)。
这项全国范围内基于人群的队列研究显示,与参考 TI≤32 天相比,TI>32 天的患者死亡风险略有增加,但无统计学意义。最强的预后因素是手术后残余肿瘤和 FIGO 分期。总体 5 年生存率为 42.8%(95%CI:38.9%;46.5%)。